Psychedelic Medicine
March 28, 2026
Levi Neal, Hannah E. Shaw, Brenda M. Gannon et al.
Background: There are currently three FDA-approved medications for opioid use disorder (OUD), but none of them are especially effective, some can precipitate withdrawal in dependent individuals, and all of them require daily administration. In the appropriate settings, single administrations of psychedelics can elicit persistent anti-addiction effects in humans and in laboratory animals, but...
bioRxiv (Cold Spring Harbor Laboratory)
March 5, 2026
Venkatesh Subramani, Annalisa Pascarella, Jérémy Brunel et al.
Abstract Psychedelics profoundly alter conscious experience, yet how they reshape the relationship between brain anatomy and function remains unclear. In particular, it is unknown whether psychedelic states reflect a global disruption of structure–function organization or a frequency– and network-specific reconfiguration of neural dynamics relative to the structural connectome. Here we address...
Psychedelic Medicine
March 1, 2026
Brian S. Barnett, Akhil Anand, Elizabeth N. Dewey et al.
Objective: While data on perceived availability of lysergic acid diethylamide (LSD) [paLSD] are collected annually in the United States, detailed investigations of recent trends in paLSD have not been published. Therefore, we sought to explore this topic. Method: Data were sourced from the 2015–2019 National Survey on Drug Use and Health (NSDUH) administrations. To identify factors associated...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2026
Jonah Griffin-Stolbach, Hanna Molla, Donald Hedeker et al.
There has been great interest in the use of very low doses of psychedelic drugs like lysergic acid diethylamide (LSD) to improve mood and cognition. However, controlled studies have thus far provided little support for their efficacy. One challenge is that the subjective effects are subtle and on the threshold of detectability, whereas the questionnaires used to assess the drugs' effects were...
Drug and Alcohol Dependence Reports
March 1, 2026
Jing-Jer Chen, Carla J. Berg, Y Tony Yang
1 citation
While interest in the therapeutic and recreational use of hallucinogens has increased, national surveillance often reports use in aggregate, potentially masking shifting trends among pharmacologically distinct substances. This study assessed trends in specific hallucinogens from 2021 to 2023 and identified correlates of use, with particular attention to subgroup patterns in populations commonly...